Table of Contents :
• Stock Rating & Target Price
• Investment Thesis
• Fundamental Models Used
• Company Description
• Corporate Timeline
• Key Metrics (KPI ) and Recently Reported Earnings Review
• Business Highlights, Strategic Announcements & Outlook
• Quarter-over-Quarter (Q-o-Q) and Year-over-Year (Y-o-Y) Growth Analysis
• Key Catalysts Driving Growth
• Historical Financial Statement Analysis & CAGR Trends
• Quarterly Key Financial Ratios and Performance Metrics
• Annual Financial Performance Analysis: Horizontal and Vertical Financial Analysis, Trends
• Financial Forecasts
• Annual Forecasts: Income Statement
• Annual Forecasts: Cash Flow Statements
• Net Debt Levels
• A Closer Look at DCF: Our Assumptions and Methodology
• Terminal Value Calculation
• Target Price Analysis
• Valuation Multiples
• Supplementary Valuation Analysis: Multiples Approach
• Scenario/Sensitivity Analysis – Base Case , Bull Case ,Bear Case
• Holistic Peer Review & Trading Comps: Financial Data, Operational Metrics, and Valuation Multiples
• Implied Price Per Share
• Ownership Activity/ Insider Trades
• Ownership Summary
• An analysis of ESG Risk Rating
• Key Professionals
• Key Board Members
• Key Risks Considerations
• Analyst Ratings
• Analyst Industry Views
• Disclosures
Albertsons Companies Inc (ACI): Pharmacy & E-Comm Strength Mask Margin Erosion—What’s the Impact, Valuation Outlook & its 5 Key Catalysts ?
Albertsons (ACI) delivered a Q1 FY25 print that beat on identical sales growth at +2.8% (vs. 1.5–2.5% guided), driven by strength in pharmacy (+20% YoY) and digital (+25% YoY), highlighting traction in loyalty, mobile integration, and GLP-1 prescriptions. While gross margins compressed 85bps YoY (ex-fuel/LIFO) to 27.1%, driven by mix headwinds and proactive loyalty pricing, SG&A leverage and early productivity gains partially offset the impact. Adjusted EBITDA of $1.11B and EPS of $0.55 were in line with reiterated full-year guidance ($3.8B–$3.9B EBITDA, $2.03–$2.16 EPS), implying margin reacceleration in H2. Loyalty users rose 14% YoY to 47M, and retail media growth via Media Collective is gaining CPG traction. Pharmacy is increasingly core to engagement, with cross-shoppers showing 4x higher frequency. Centralized fill hubs and national procurement strategy should unlock further leverage. Capex was $585M, focused on automation and tech modernization. Net leverage improved to 1.96x, and capital returns totaled $401M. Despite omnichannel execution, margin durability remains constrained amid pricing pressure, flat core grocery growth, and limited operating leverage. Even with higher ID sales guidance (2.0–2.75%), long-term margin upside remains capped. Can Albertsons convert strategic investments in loyalty, pharmacy, and media into sustained EBITDA growth despite structurally tight grocery margins?
